CN121534175A - 用于调节调节性t细胞和抑制肿瘤生长的方法 - Google Patents

用于调节调节性t细胞和抑制肿瘤生长的方法

Info

Publication number
CN121534175A
CN121534175A CN202511335959.5A CN202511335959A CN121534175A CN 121534175 A CN121534175 A CN 121534175A CN 202511335959 A CN202511335959 A CN 202511335959A CN 121534175 A CN121534175 A CN 121534175A
Authority
CN
China
Prior art keywords
cancer
cells
tregs
treg
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511335959.5A
Other languages
English (en)
Chinese (zh)
Inventor
P-C·何
H·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Lausanne
Original Assignee
Universite de Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Lausanne filed Critical Universite de Lausanne
Publication of CN121534175A publication Critical patent/CN121534175A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202511335959.5A 2018-09-14 2019-09-13 用于调节调节性t细胞和抑制肿瘤生长的方法 Pending CN121534175A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862731351P 2018-09-14 2018-09-14
US62/731,351 2018-09-14
CN201980060377.7A CN112703039A (zh) 2018-09-14 2019-09-13 用于调节调节性t细胞和抑制肿瘤生长的方法
PCT/IB2019/057745 WO2020053833A1 (en) 2018-09-14 2019-09-13 Methods for modulating regulatory t cells and inhibiting tumor growth

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980060377.7A Division CN112703039A (zh) 2018-09-14 2019-09-13 用于调节调节性t细胞和抑制肿瘤生长的方法

Publications (1)

Publication Number Publication Date
CN121534175A true CN121534175A (zh) 2026-02-17

Family

ID=68393033

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511335959.5A Pending CN121534175A (zh) 2018-09-14 2019-09-13 用于调节调节性t细胞和抑制肿瘤生长的方法
CN201980060377.7A Pending CN112703039A (zh) 2018-09-14 2019-09-13 用于调节调节性t细胞和抑制肿瘤生长的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980060377.7A Pending CN112703039A (zh) 2018-09-14 2019-09-13 用于调节调节性t细胞和抑制肿瘤生长的方法

Country Status (7)

Country Link
US (1) US20220049010A1 (https=)
EP (1) EP3849666B1 (https=)
JP (2) JP2022500448A (https=)
CN (2) CN121534175A (https=)
AU (2) AU2019340475B2 (https=)
CA (1) CA3109563A1 (https=)
WO (1) WO2020053833A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
WO2021152548A1 (en) * 2020-01-30 2021-08-05 Benitah Salvador Aznar Combination therapy for treatment of cancer and cancer metastasis
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
KR20070022197A (ko) * 2003-11-05 2007-02-26 팔링겐, 인코포레이티드 Ｃｄｉｍ 결합 항체의 증강된 ｂ 세포 세포독성
JP2008521814A (ja) * 2004-11-24 2008-06-26 シェーリング コーポレイション Ｄａｐ−１０およびその使用
JP2012149004A (ja) * 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤
CA2988119A1 (en) * 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
EP3650468A1 (en) * 2015-09-29 2020-05-13 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Targeting metastasis stem cells through a fatty acid receptor (cd36)
WO2018029336A1 (en) * 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
GB201802307D0 (en) * 2018-02-13 2018-03-28 Vib Vzw CD36 antagonists for use in melanoma treatment

Also Published As

Publication number Publication date
AU2019340475A1 (en) 2021-03-11
JP2024153816A (ja) 2024-10-29
CN112703039A (zh) 2021-04-23
EP3849666A1 (en) 2021-07-21
WO2020053833A1 (en) 2020-03-19
CA3109563A1 (en) 2020-03-19
EP3849666B1 (en) 2026-04-15
US20220049010A1 (en) 2022-02-17
AU2019340475B2 (en) 2025-04-17
AU2025205589A1 (en) 2025-08-07
JP2022500448A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
US11065285B2 (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation
Piconese et al. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
AU2025205589A1 (en) Methods for modulating regulatory T cells and inhibiting tumor growth
JP2020164539A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
US20240262909A1 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
US11986538B2 (en) Immunoswitch nanoparticles for reprogrammed T cell responses
JP2019528288A (ja) がん免疫療法のための組成物および方法
WO2020086440A1 (en) Immunomodulatory compounds
Tang et al. Anti-CD20 monoclonal antibody combined with adenovirus vector-mediated IL-10 regulates spleen CD4+/CD8+ T cells and T-bet/GATA-3 expression in NOD mice
Xu et al. The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis
HK40045698A (en) Methods for modulating regulatory t cells and inhibiting tumor growth
CN118317778A (zh) 工程化nk细胞及其用途
EP4389122A1 (en) Adiponectin alone or in combination with extracorporeal photopheresis (ecp) for immune related adverse events of immune checkpoint inhibitors
JP2017526702A (ja) ＰＰＡＲ−γアゴニストを投与する段階を含む、癌を治療する方法
US20240307497A1 (en) Adiponectin alone or in combination with extracorporeal photopheresis (ecp) for immune related adverse events of immune checkpoint inhibitors
Hasegawa et al. Expressions of multidrug resistance protein 1 and multidrug resistance-associated protein 1 in lung dendritic cells
TW202417643A (zh) 用於將免疫療法最佳化之因素
HK40018875A (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation
WO2020146772A1 (en) Neuritin regulation of t cell anergy and t regulatory cell function
HK1204577B (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination